Reviewer’s report

Title: Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis

Version: 1 Date: 3 August 2014

Reviewer: Kayoko Hayakawa

Reviewer’s report:

Authors conducted a systematic review and meta-analysis on treatment of vancomycin-resistant enterococcal bacteremia comparing daptomycin to linezolid. The study endpoints were mortality and microbiological cure. A meta-analysis of the 13 available studies indicates that linezolid is superior to daptomycin in protection against mortality from VRE bacteremia.

Major Compulsory Revisions:
Figure 2. Manuscript of Mave was published in 2009, not 2007. Also, a ORs authors have referred are actually different from what were written in the original manuscripts.
(e.g. According to original paper of Mave at al, aOR is 1.71 [0.56-5.19], not 5.22). Similarly, Mckinnell reported aOR as 2.1 (0.99-4.70), not 4.45. Please check one more time carefully for referring original data.

Discretionary Revisions
It might be beneficial to mention more on “Confounding by Indication ”(PMID 24982037). Sicker patients were included in the daptomycin groups as compared to linezolid group in the recent studies on VRE bacteremia which authors have referred. It would be quite possible that some residual confoundings exist even after adjusting my multivariate regression in each study.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:
I declare that I have no competing interests